0.1000
0.0000
(0.00%)
At close: April 8 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2022
12/31/2021
12/31/2020
Total Revenue
604.9800
604.9800
116.2110
1,203.3880
Cost of Revenue
29,502.3220
29,502.3220
18,455.6400
13,307.8640
Gross Profit
-28,897.3420
-28,897.3420
-18,339.4290
-12,104.4760
Operating Expense
1,185.7710
1,185.7710
836.9330
1,753.0950
Operating Income
-30,083.1130
-30,083.1130
-19,176.3620
-13,857.5710
Net Non Operating Interest Income Expense
-393.8630
-393.8630
-8.4170
-5.0860
Pretax Income
-30,481.0060
-30,481.0060
-19,184.7780
-13,862.6580
Tax Provision
-2,549.2140
-2,549.2140
-2,661.7990
-2,147.5420
Net Income Common Stockholders
-24,935.4990
-24,935.4990
-16,555.7270
-11,536.7010
Diluted NI Available to Com Stockholders
-24,935.4990
-24,935.4990
-16,555.7270
-11,536.7010
Basic EPS
-0.72
-0.72
-0.61
-0.43
Diluted EPS
-0.72
-0.72
-0.61
-0.43
Basic Average Shares
34,763.6790
34,763.6790
27,345.4130
26,712.4890
Diluted Average Shares
34,763.6790
34,763.6790
27,345.4130
26,712.4890
Total Operating Income as Reported
-30,083.1700
-30,083.1700
-19,187.0260
-13,857.6550
Total Expenses
30,688.0930
30,688.0930
19,292.5730
15,060.9590
Net Income from Continuing & Discontinued Operation
-27,931.7910
-27,931.7910
-16,522.9790
-11,715.1160
Normalized Income
-27,931.7910
-27,931.7910
-16,522.9790
-11,715.1160
Interest Income
0.1700
0.1700
4.9880
5.5770
Interest Expense
17.6720
17.6720
13.3500
--
Net Interest Income
-393.8630
-393.8630
-8.4170
-5.0860
EBIT
-30,463.3340
-30,463.3340
-19,171.4280
-13,857.5710
EBITDA
-30,199.5610
-30,199.5610
-18,906.2710
-13,687.5710
Reconciled Cost of Revenue
29,502.3220
29,502.3220
18,455.6400
13,307.8640
Reconciled Depreciation
263.7730
263.7730
265.1570
170
Net Income from Continuing Operation Net Minority Interest
-27,931.7910
-27,931.7910
-16,522.9790
-11,715.1160
Normalized EBITDA
-30,199.5610
-30,199.5610
-18,906.2710
-13,687.5710
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0002
12/31/2020 - 5/19/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
88Q.DU 4basebio PLC
13.10
+1.55%
ELIC.ST Elicera Therapeutics AB (publ)
2.9450
-1.83%
BIOS.BR BioSenic S.A.
0.0019
0.00%
CYAD.BR Celyad Oncology SA
0.4970
0.00%
DBV.PA DBV Technologies S.A.
1.2780
-0.47%
ONT.L Oxford Nanopore Technologies plc
107.20
+8.94%
PHM.MC Pharma Mar, S.A.
75.30
+3.86%
DBVT DBV Technologies S.A.
7.15
-3.97%
ARGX argenx SE
548.93
-0.19%
TNXP Tonix Pharmaceuticals Holding Corp.
19.82
+11.35%